Hyperfractionated or accelerated radiotherapy in head and neck cancer:: a meta-analysis

被引:782
作者
Bourhis, Jean
Overgaard, Jens
Audry, Helene
Ang, Kian K.
Saunders, Michele
Bernier, Jacques
Horiot, Jean-Claude
Le Maitre, Aurlie
Pajak, Thomas F.
Paulsen, Michael G.
O'Sullivan, Brian
Dobrowsky, Werner
Hliniak, Andrzej
Skladowski, Krzysztof
Hay, John H.
Pinto, Luiz H. J.
Fallai, Carlo
Fu, Karen K.
Sylvester, Richard
Pignon, Jean-Pierre
机构
[1] Inst Gustave Roussy, Dept Biostat & Epidemiol, F-94805 Villejuif, France
[2] Inst Gustave Roussy, Dept Radiat Oncol, Villejuif, France
[3] Danish Canc Soc, Dept Expt Clin Oncol, DK-8000 Aarhus, Denmark
[4] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[5] Mt Vernon Hosp, Northwood HA6 2RN, Middx, England
[6] Univ Geneva, Fac Med, CH-1211 Geneva 4, Switzerland
[7] Ctr F Leclerc, Dijon, France
[8] RTOG Stat Headquarters, Philadelphia, PA USA
[9] So Zone Radiat Oncol Mater Ctr, Brisbane, Qld, Australia
[10] Princess Margaret Hosp, Dept Radiat Oncol, Toronto, ON M4X 1K9, Canada
[11] Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England
[12] Oncol Inst Ctr, Warsaw, Poland
[13] Maria Curie Mem Inst, Gliwice, Poland
[14] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[15] Inst Nacl Canc, Rio De Janeiro, Brazil
[16] Ist Nazl Tumori, Dipartimento Radiotherapia, I-20133 Milan, Italy
[17] Univ Calif San Francisco, San Francisco, CA 94143 USA
[18] EORTC Stat Headquarters, Brussels, Belgium
关键词
D O I
10.1016/S0140-6736(06)69121-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Several trials have studied the role of unconventional fractionated radiotherapy in head and neck squamous cell carcinoma, but the effect of such treatment on survival is not clear. The aim of this meta-analysis was to assess whether this type of radiotherapy could improve survival. Methods Randomised trials comparing conventional radiotherapy with hyperfractionated or accelerated radiotherapy, or both, in patients with non-metastatic HNSCC were identified and updated individual patient data were obtained. Overall survival was the main endpoint. Trials were grouped in three pre-specified categories: hyperfractionated, accelerated, and accelerated with total dose reduction. Findings 15 trials with 6515 patients were included. The median follow-up was 6 years. Tumours sites were mostly oropharynx and larynx; 5221 (74%) patients had stage III-IV disease (International Union Against Cancer, 1987). There was a significant survival benefit with altered fractionated radiotherapy, corresponding to an absolute benefit of 3.4% at 5 years (hazard ratio 0.92, 95% CI 0.86-0.97; p=0.003). The benefit was significantly higher with hyperfractionated radiotherapy (8% at 5 years) than with accelerated radiotherapy (2% with accelerated fractionation without total dose reduction and 1.7% with total dose reduction at 5 years, p=0.02). There was a benefit on locoregional control in favour of altered fractionation versus conventional radiotherapy (6.4% at 5 years; p<0.0001), which was particularly efficient in reducing local failure, whereas the benefit on nodal control was less pronounced. The benefit was significantly higher in the youngest patients (hazard ratio 0.78 [0.65-0.94] for under 50 year olds, 0.95 [0.83-1.09] for 51-60 year olds, 0.92 [0.81-1.06] for 61-70 year olds, and 1.08 [0.89-1.30] for over 70 year olds; test for trends p=0.007). Interpretation Altered fractionated radiotherapy improves survival in patients with head and neck squamous cell carcinoma. Comparison of the different types of altered radiotherapy suggests that hyperfractionation has the greatest benefit.
引用
收藏
页码:843 / 854
页数:12
相关论文
共 29 条
[1]  
ABE O, 1995, NEW ENGL J MED, V333, P1444
[2]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[3]  
[Anonymous], 1992, Lancet, V339, P1
[4]  
BOURHIS J, 2004, P AN M AM SOC CLIN, V22, P488
[5]  
Bourhis J, 2006, J CLIN ONCOL, V24, p280S
[6]   Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: A GORTEC trial [J].
Bourhis, Jean ;
Lapeyre, Michel ;
Tortochaux, Jacques ;
Rives, Michel ;
Aghili, Mehdi ;
Bourdin, Sylvain ;
Lesaunier, Francois ;
Benassi, Toufik ;
Lemanski, Claire ;
Geoffrois, Lionel ;
Lusinchi, Antoine ;
Verrelle, Pierre ;
Bardet, Etienne ;
Julieron, Morbize ;
Wibault, Pierre ;
Luboinski, Monique ;
Benhamou, Ellen .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2873-2878
[7]  
Cummings B., 2000, Radiotherapy and Oncology, V56, pS8
[8]  
DATTA N R, 1989, International Journal of Radiation Oncology, Biology, Physics, V17, P132
[9]   A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer [J].
Dische, S ;
Saunders, M ;
Barrett, A ;
Harvey, A ;
Gibson, D ;
Parmar, M .
RADIOTHERAPY AND ONCOLOGY, 1997, 44 (02) :123-136
[10]   Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers [J].
Dobrowsky, W ;
Naudé, J .
RADIOTHERAPY AND ONCOLOGY, 2000, 57 (02) :119-124